Home > Publications database > The Role of Radionuclide Diagnostic Methods in Neuro-Oncology > print

001     885928
005     20230111074319.0
024 7 _ |a 10.20862/0042-4676-2020-101-4-221-234
|2 doi
024 7 _ |a 2128/27572
|2 Handle
037 _ _ |a FZJ-2020-04184
082 _ _ |a 610
100 1 _ |a Ю. Скворцова, T.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a The Role of Radionuclide Diagnostic Methods in Neuro-Oncology
260 _ _ |a Moskva [u.a.]
|c 2020
|b Medicina
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1618235232_21836
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In recent years, positron emission tomography (PET) with amino acid radiopharmaceuticals has assumed increasing importance in the diagnosis of brain tumors and it has already become an additional method of examination along with magnetic resonance imaging (MRI) in many diagnostic centers. The markers of somatostatin receptors seem to be most promising for the PET diagnosis of meningiomas. PET provides important additional information in the diagnosis of brain changes of unknown origin and more accurate information about tumor boundaries, which is necessary for biopsy, neurosurgery, and radiation therapy. In addition, labeled amino acid PET aids in the assessment of disease prognosis, in the differentiation of continued tumor growth from nonspecific therapeutic pathomorphism of the brain, and in the evaluation of treatment efficiency at an earlier time than is possible with MRI.
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Judov, Natalie
|0 P:(DE-Juel1)143958
|b 1
|u fzj
700 1 _ |a Plotkin, M.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Stoffels, Gabriele
|0 P:(DE-Juel1)131627
|b 3
|u fzj
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 4
|u fzj
700 1 _ |a Красикова, Р. Н.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 6
|e Corresponding author
|u fzj
773 _ _ |a 10.20862/0042-4676-2020-101-4-221-234
|g Vol. 101, no. 4, p. 221 - 234
|0 PERI:(DE-600)128671-7
|n 4
|p 221 - 234
|t Vestnik rentgenologii i radiologii
|v 101
|y 2020
|x 0042-4676
856 4 _ |u https://juser.fz-juelich.de/record/885928/files/573-1689-1-SM.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:885928
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)143958
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131627
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)143792
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131777
913 0 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-500
|4 G:(DE-HGF)POF
|v Neuroimaging
|x 0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 0
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21